Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model - Wikidata - awgldk - TriplyDB

Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model

Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model

http://www.wikidata.org/entity/Q57691250

about

HIF prolyl hydroxylase inhibitors for anemia Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.Expression of a novel stress-inducible protein, sestrin 2, in rat glomerular parietal epithelial cells.Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.HIV-associated nephropathy: role of AT2R.Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis Sirolimus modulates HIVAN phenotype through inhibition of epithelial mesenchymal transition.ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.Inhibition of renin activity slows down the progression of HIV-associated nephropathy Inhibition of Notch pathway attenuates the progression of human immunodeficiency virus-associated nephropathy.Urinary exosomal transcription factors, a new class of biomarkers for renal disease.Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis.Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.Therapeutic targets in focal and segmental glomerulosclerosis.Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury.Focal Segmental Glomerulosclerosis.Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy.Presentation of HIV-associated nephropathy and outcome in HAART-treated patients.APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.SIRPα signaling regulates podocyte structure and function.HIV-1 and kidney cells: better understanding of viral interaction.Molecular Mechanisms of Injury in HIV-Associated Nephropathy.Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy

P2860

Q28307377-17364B8E-98CA-42C7-B982-539F31560CF7 Q33920991-D6A2F828-2A49-4A81-96A9-9DE6D4F15375 Q34200992-D66AE8C7-848B-4FA9-9B6E-90B8128F6AFB Q34211611-46FE347B-7990-4686-B12B-C878432FC624 Q34957142-053106AD-F345-45DF-8B67-E148E4F0E399 Q35235668-20B36F51-0F82-40EC-BB25-EEB2D4ABE606 Q35672941-3A91E34C-F2BD-4649-9A7E-14713988232D Q35868694-14B49E0A-9C42-459D-9276-F585F32A2CA7 Q36024762-A1F38463-4310-47CF-AE95-5AB593014BA5 Q36129864-60D31E41-127A-4136-B81D-74379BA41488 Q36309378-825E9B71-65BA-4160-9BFE-A8E67D0255DC Q36764212-B2D16477-1455-496E-9AD0-FEAAACF961DD Q36926455-3EA2777E-AD81-4E23-9EC7-AF66242D778F Q37071676-1069567E-84CF-477D-BEE0-AA947CA527FF Q37095455-08D84B89-3563-4CFD-8B29-D7C708C393C0 Q37228164-ECA64451-B467-4A70-A4E1-7555E03B12D1 Q37476603-8C32C462-72F6-48D7-98EF-1EEFD3BFDA7B Q38938623-C9EAA61C-572F-4F50-9654-392DFEA431D3 Q42448757-C5BB00DF-AE0C-4454-8B8F-450545416162 Q46900629-D2083DB9-2935-436A-9234-D2FAEC89BD62 Q47432449-F18AFF8D-2F37-457A-8FD3-4166150EFE60 Q48030981-30110587-7558-4BBF-B4BF-D9A5C5666717 Q53473056-958741C2-B871-4970-AA23-B3C6101BD4C6 Q55405435-4A1DA4C5-6D60-46A9-B59E-014B5EC19C29 Q57691243-2B0FA77E-A5C0-425F-997C-59E59B0B757D

P2860

Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model

http://www.wikidata.org/entity/Q57691250

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2007

@uk

name

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@en

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@nl

type

label

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@en

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@nl

prefLabel

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@en

Angiotensin II Type 1 Receptor ...... d Nephropathy in a Mouse Model

@nl

P1433

Q57691250-F130D445-A671-4805-96AF-C392B40A026E

P1476

Q57691250-9E4A0A7F-1A4C-4E5D-AB89-D1ACDFFAC473

P2093

Q57691250-0320BF5A-57CC-4032-8B60-3ADBB6917202

Q57691250-569A49D7-5B5A-4898-B293-5F8561B4A202

Q57691250-6E4BDB63-8E7D-4419-8C7B-4064185A5C6A

Q57691250-78BFF9C2-A9C5-4F20-BD50-812FECBFFC34

Q57691250-7ED2EF6C-4EEC-4F91-99A7-DE00D413713C

Q57691250-846730A2-491D-4A70-AE56-503C205E5702

Q57691250-85BBFF9D-8948-496C-8C8F-0183FAD03364

Q57691250-9AB4C20F-0D5D-4969-BE32-CAFE15A77A5B

Q57691250-A173E7D1-F421-4B97-998E-E69A2E9E9731

Q57691250-DCE787E2-B20D-42E8-8F84-6140B95C0D58

P304

Q57691250-3C012023-A211-44DC-B319-1A4207880185

P31

Q57691250-5E58A017-C5B2-4AE8-975B-9EC9605ECF58

P356

Q57691250-A0A38D8F-12D3-4741-9ADC-16129167EB4B

P433

Q57691250-F0A0DFBE-B885-4C76-8B0C-831F0F2C47BA

P478

Q57691250-CE73122F-CB68-4F21-8012-DE0F94DB0D93

P50

Q57691250-1247F920-CA2C-458D-A597-5B8C47792D7E

Q57691250-8D60C71F-3E0C-48F1-9AEF-E3ECE3625AC8

P577

Q57691250-64ADE8D1-50D0-45DF-997F-EAD9B92C5DD2

P698

Q57691250-686143FB-F6DE-4114-A6CC-39BA7A8D6AAE

P356

P1433

Journal of the American Society of Nephrology

P1476

Angiotensin II type 1 receptor ...... d nephropathy in a mouse model

@en

P2093

Hiroshi Ideura

http://www.w3.org/2001/XMLSchema#string

Kazue Ueki

http://www.w3.org/2001/XMLSchema#string

Keiju Hiromura

http://www.w3.org/2001/XMLSchema#string

Mai Tomioka

http://www.w3.org/2001/XMLSchema#string

Noriyuki Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Noriyuki Sakurai

http://www.w3.org/2001/XMLSchema#string

Shigeru Takeuchi

http://www.w3.org/2001/XMLSchema#string

Takashi Kuroiwa

http://www.w3.org/2001/XMLSchema#string

Tetsuya Shigehara

http://www.w3.org/2001/XMLSchema#string

Yoriaki Kaneko

http://www.w3.org/2001/XMLSchema#string

P304

515-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2006030217

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey B. Kopp

Hidekazu Ikeuchi

P577

2007-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17229913

http://www.w3.org/2001/XMLSchema#string